Booster of Sipuleucel-T increases the number of enriched T-Cell clones fostering immunologic memory in #mCRPC SITC #ImmunoOnc18
See you in a few days at #ImmunoOnc18 in San Francisco stop by our poster, #TNBC #bcsm
Phenotypic differences in tumor-associated macrophages between metastatic and primary sites of clear cell #RCC #kidneycancer #ImmunoOnc18
Phase 2 study w the autophagy inhibitor HCQ + IL-2 in mRCC shows good tolerance and aims to evaluate survival data, toxicity data, and biomarkers/autophagy measures. #KidneyCancer #ImmunoOnc18
Poor prognostic metastatic-like DDRD subgroup characterized primarily by variances in copy number and genomic mutation represent viable target population for immune checkpoint and DNA damaging therapies in #prostatecancer. #ImmunoOnc18
Recruiting Trial: A pilot study recruiting to evaluate MDSC clinical assay for cancer detection and monitoring in urothelial carcinoma #BladderCancer ??? #ImmunoOnc18
High ERV expressing group showed evidence of immune activation and may be associated w response to immune checkpoint therapy in #RCC #Kidneycancer #ImmunoOnc18
An expansion cohort of #mesothelioma patients (n=53) treated with #Avelumab showed clinical activity and acceptable safety in pts with previously treated mesothelioma. #ImmunoOnc18
A TGR/OS as survival model for atezolizumab as an early predictor of OS of 1L/2L for MUC #bladdercancer #ImmunoOnc18
Optimized administration sequence and timing of active DC immunotherapy with a PD1 checkpoint inhibitor in a mouse model of #RCC #kidneycancer #ImmunoOnc18